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Abstract 
 
Background: New optical techniques of spectroscopy have shown promising results 
in the evaluation of solid tumours. 
Objective: To evaluate the potential of Raman spectroscopy (RS) to assess renal 
tumours at surgery. 
Design, setting, and participants: Over a 5 months period, Raman optical spectra 
were prospectively acquired on surgical renal specimen removed due to suspicion of 
cancer. 
Measurements: Raman measures were normalized to ensure comparison between 
spectra. A lower resolution signal was computed using a wavelet decomposition 
procedure to diminish the size of the signal and exploit the complete spectrum. A 
support vector machine (SVM) with a linear kernel and a sequential minimal 
optimization solver was applied. A leave-one-out cross validation technique was used 
to train and test the SVM. 
Results and limitations: There were 36 patients with 34 malignant (27 clear cell, 6 
papillary and one chromophobe) and two benign (one oncocytoma and one 
metanephric cyst) tumours. A total of 241 analyzable Raman spectra were obtained. 
The SVM was able to classify tumoural and normal tissue with an accuracy of 84% 
(sensitivity 82%, specificity 87%). High grade and low grade tumours were 
differentiated with a precision of 82% (sensitivity 84%, specificity 80%). Histologic 
subtype could be categorized with an accuracy of 93% (sensitivity 96%, specificity 
87%). SVM could not be applied to classify benign and malignant tumours because 
of the restricted number of benign spectra. 
Conclusions: RS can accurately differentiate normal and tumoural renal tissue, low 
grade and high grade renal tumours, as well as histologic subtype of RCC. Larger 
prospective studies are needed to confirm these preliminary data. 
 
Introduction 
 
The natural course of cancer is hardly predictable. This is particularly true for 
renal cell carcinoma (RCC) where 40% of affected individuals will die from their 
disease [1]. A better understanding of molecular pathways has led to the 
development of multiple targeted therapies with significant clinical benefits [2]. 
However, response to treatment is only seen in a minority of patients and side effects 
are frequent and cumbersome. In an effort to better appraise the evolution of RCC in 
a specific patient, a prognostic role has been suggested for various biomarkers, 
mostly genes and proteins [3]. Some of these biomarkers have been integrated to 
predictive models but since they hold many imperfections, they are not used in 
clinical practice. There is therefore a clear need for new predictive tools and/or 
different conceptual approaches to address RCC, and more generally cancer [4, 5]. 
Raman spectroscopy (RS) is based on molecular inelastic scattering of light 
[6]: when photons interact with a molecule, the transmission of their energy raises the 
molecule’s vibrational state. When the molecule returns to its background level, a 
photon is emitted at a different wavelength from the incident light. This change in 
wavelength is known as the Raman effect or Raman shift. All Raman shifts 
generated by the interaction of light with tissue provide a Raman spectrum (figure 1) 
that is directly related to the molecular composition of the tissue. Promising results 
have been reported with RS for in vitro and ex vivo assessment of various solid 
tumours [7-9]. In this study, we investigated the potential of RS to evaluate normal 
and tumoural renal tissue on surgically removed specimen.  
 
 
 
Materials and methods 
Instrumentation 
A Raman spectroscopic system was used to acquire immediate Raman 
spectra from kidney specimen removed at surgery. The system comprised three 
components: 1) a high-powered near-infrared laser (Invictus NIR laser 785 nm, 500 
mW, Kaiser Optical Systems, Ann Arbor, Michigan, USA) that minimizes 
fluorescence, 2) a fiber optics MR probe with a 10x non-contact objective, and 3) a 
RXN1 Raman analyzer (Kaiser Optical Systems, Ann Arbor, Michigan, USA) 
including a CCD Camera (Chip 1024x128 EEV MMP type, pixel size 26 µm) to 
receive reflected and scattered light.  
 
Specimens 
After approval by our institutional review board, we prospectively collected 
Raman spectra in consecutive kidney specimen removed due to suspicion of cancer. 
Between June and November 2009, 43 operations were performed, including 31 
radical nephrectomies and 12 partial nephrectomies. The surgery was completed 
through an open access in 22 patients and laparoscopically in 21 patients. Seven 
patients were excluded from the study based on final histology results: four with 
urothelial carcinoma, one with liposarcoma, one with a multicystic non malignant 
lesion and one with inflammatory cyst. Immediately after extraction, the specimen 
were stored on ice and transferred to the pathology department. Raman spectra were 
acquired within 15 minutes after extraction.  
 
 
 
Raman measurements 
After longitudinal section of the specimen, Raman spectra were acquired by 
placing the MR probe at several standardized locations on the surface and on the 
section of normal and tumoural tissue. No pre-treatment was performed prior to 
spectral acquisition. Four Raman measures were made, including 2 inside the 
tumour section and 2 on the normal parenchyma section. Two spectra were recorded 
on each spot. The laser beam was set at a power of 50 mW and, and focused on a 
500 µm spot on the surface of the sample. The acquisition period for Raman spectra 
was 30s, with a 4 cm-1 spectral resolution over a 150-3400 cm-1 Raman shift range.  
A wavelength of 785 nm was chosen to avoid background fluorescence. 
 
Statistical analysis 
The Raman spectrum is a plot of the intensity of the scattered light as a 
function of the difference of energy between incident and scattered light, measured in 
wave numbers (cm-1). Every peak in the spectrum corresponds to a specific 
molecular vibration. In this study, each Raman spectrum comprised 11769 points 
with Raman shift wave numbers ranging from 100 to 3444 cm-1.  
To ensure all spectra were comparable, a normalization step was performed 
by dividing every spectral point by the area of the total intensity of the spectrum [10]. 
After outliers were removed, we obtained a total of 241 spectra (106 normal, 135 
tumour, Table 1).  
The autofluorescence background can be removed to visualize the only 
Raman spectrum. However, in our study the autofluorescence was not removed so 
the whole signal content (including autofluorescence and Raman scattering) could 
remain intact for further steps of the analysis. This unusual approach offers two 
advantages: 1) it avoids any approximation error related to background removal and 
2) a potentially significant background information is preserved and incorporated to 
further steps of the analysis. All normalized spectra (normal parenchyma and tumour) 
are shown in Figure 2. 
Because of the huge size of the normalized signal (11769 points), a lower 
resolution signal was computed using a wavelet decomposition procedure. A discrete 
wavelet transformation (Daubechies three mirrors conjugate filter) [11] was applied to 
each spectrum, and the 6th level approximation (188 points) was retained to replace 
the original spectrum. This procedure removes high frequency components 
(particularly noise) in order to study the entire spectrum instead of restricted areas.  
Our objective was to generate a Raman classification of : 1) normal and 
tumoural renal tissue, 2) benign and malignant renal tumours, 3) high grade 
(Fuhrman 3-4) and low grade (Fuhrman 1-2) tumours and 4) clear cell, papillary and 
chromophobe tumours. For that purpose, a support vector machine (SVM) with a 
linear kernel and a sequential minimal optimization solver was applied to available 
Raman spectra [12]. A leave-one-out cross validation technique was used to train 
and test the SVM. For every classification, all spectra but one were used to train the 
SVM and the remaining spectrum was set aside for final testing. The process was 
repeated with alternation of the testing spectrum. At the end of the procedure, a 
cross-validation score that represents the ability of a single Raman spectrum to 
classify the assessed biological sample was obtained.  
 
Results 
Clinical and pathological characteristics of the population are depicted in table 
2.  
Histology was malignant in 34 cases (27 clear cell carcinomas, six papillary 
tumours, and one chromophobe carcinoma), and benign in two cases (one 
oncocytoma and one metanephric adenoma).  
Figure 2 displays processed tumoural and normal parenchyma Raman 
spectra. The SVM could identify normal and tumoural optical signals with an 
accuracy of 84% (sensitivity and specificity of 82 and 87% respectively).  
Low grade (Furhman 1-2) and high grade (Furhman 3-4) tumours could be 
recognized with an accuracy of 82% (sensibility and specificity of 84 and 80%, 
respectively, Figure 3).  
Histologic subtype (classified as clear cell carcinoma vs. papillary or 
chromophobe) was distinguished with an accuracy of 93% (sensibility and specificity 
of 96 and 87%, respectively, Figure 4).  
The SVM could not be applied to classify benign and malignant tumours 
because the number of benign spectra was too small to train the model.  
 
 
 
Discussion 
 Despite all the progresses made over the last decades, cancer remains a 
leading cause of death and its natural course is difficult to predict in a single patient. 
The disparity in the evolution of tumours with identical clinical and pathological 
presentations is certainly related to molecular differences that we are still unable to 
detect. This is remarkably true about RCC. It is the most lethal urological tumour and 
its evolution can be quite unpredictable with 30 to 40% of patients who will develop 
metastases during follow-up although they were classified M0 at the time of surgery.  
New targeted therapies can impact tumour growth in up to 40% of metastatic RCC 
patients [2]. However, these drugs have a high toxicity, high cost and there is no tool 
that can predict response to treatment. Oncological research has focused on 
molecular biomarkers that could determine the prognosis or foretell response to 
treatment. Concerning RCC, a prognostic role has been suggested for numerous 
markers, including adhesion molecules (cadherin-6, e-cadherin, ICAM-1), receptors 
of growth factors (VEGFR-3, TGFBR-2), hypoxia inducible molecules (CA9, VEGF, 
IGF-1) or proliferation markers (Ki-67, PCNA) [3]. Still, many limitations restrict their 
use in clinical practice.  For this reason, many experts in cancer research expect 
conceptual changes in the approach of cancer.  
 RS is an optical technique based on inelastic scattering (the so-called Raman 
effect) of monochromatic light (usually emitted by a laser in the visible or near 
infrared range) interacting with a biological sample. When light is targeted on tissue 
molecules, a small fraction of the scattered light undergoes shifts in its frequency. 
The amplitude of these Raman shifts corresponds to vibrations of intramolecular 
bonds. Every molecule has a unique vibrational energy state to which corresponds a 
specific Raman shift. As such, the Raman spectrum is a direct function of the 
molecular composition of the tissue and functional and structural changes may be 
evidenced by a change in Raman optical signature.  Promising results have been 
reported with RS in the evaluation of urological tumours. RS has been shown to 
identify in vitro malignant changes in the urothelium [8] and prostate biopsy cores [9].  
In another study, RS could recognize with high accuracy benign prostatic tissue 
(benign prostatic hyperplasia and prostatitis) from prostate cancer with an accuracy 
of 86% [13].  
 In the current study, we showed that RS could accurately differentiate normal 
and tumoural renal tissue, high grade and low grade RCC, as well as histologic 
subtypes of RCC. We obtained sensitivity rates ranging from 82 to 95% and 
specificity rates ranging from 80 to 87%. We believe these results give reasons to 
expect that RS could become a valuable diagnostic method to evaluate RCC. RS has 
many advantages: 1) it gives immediate results, 2) it is an objective method using 
robust algorithms that does not need human interpretation 3) it is non-invasive and 4) 
It is non toxic and can easily be transferred to human care.  
 To our knowledge, our study is the first one that specifically reports the use of 
RS to evaluate kidney cancer. Several publications have recently presented other 
techniques of optical spectroscopy to assess renal tumours. Parekh et al used a 
combination of reflective and fluorescent spectroscopy, and noted that optical 
characteristics could differentiate benign and malignant renal tissues [14]. The team 
from the University of Texas Southwestern University successively showed that 
optical reflectance spectroscopy could accurately discriminate normal and tumoural 
renal tissue [15] and benign and malignant renal tumours at surgery [16]. Raman 
spectroscopy has the advantage that its spectrum contains very rich information that 
might be more adequate to identify molecular changes in a sample compared to 
reflectance or fluorescence spectroscopy. RS provides important biochemical 
information because each molecule has its own pattern of vibration that can serve as 
a “Raman biomarker”. Furthermore, these vibrations are usually sensitive to the 
structure of the molecular environment and can therefore reflect structural changes 
besides biochemical changes.  
RS can be pictured as an “optical biopsy tool” that has several possible 
applications in clinical urology. Given that RS can accurately distinguish normal and 
cancerous renal tissue, it could be used to assess the margin status of tumour 
resection in real time during partial nephrectomy as it has already been 
demonstrated with reflectance spectroscopy [15]. It could represent an alternative to 
frozen section analysis that lacks specificity [17]. RS could also help the pathologist 
improve diagnostic accuracy. It is well known for example that the establishment of 
Furhman grade is affected by intra and interobserver variability [18]. Finally, RS could 
be viewed as an optical biomarker of RCC. For that purpose, larger studies need to 
be undertaken to correlate optical profiles to the outcome of RCC. 
Our study has several limitations. First, it was done on ex-vivo specimen, and 
the impact of blood flow might have been underestimated. Haemoglobin is the 
preponderant chromophore and has a high ability to absorb light. For this reason, 
there is a need for in vivo studies. For that purpose, the equipment must be refined to 
be used in the sterile environment of the operating room. Second, our population of 
benign lesions was too limited to demonstrate any difference between benign and 
malignant renal tumours. We believe that with more benign cases, we would have 
been able to recognize malignant from benign because: 1) such differences have 
been demonstrated for solid urological tumours assessed by RS [8, 13], 2) benign 
and malignant renal tumours can be differentiated by the means of optical reflectance 
spectroscopy [16], and 3) the fact that tumour grade is accurately classified suggests 
that ultrastructural differences related to the malignant state of a cell or a tissue can 
be detected by RS.  
 
Conclusion 
In conclusion, our preliminary study showed that RS could accurately 
differentiate RCC from normal renal tissue. RS can also be used to classify RCC as 
low or high grade and differentiate clear cell type versus papillary or chromophobe 
tumours. Therefore, RS could have the potential to be used as a diagnostic tool to 
assist the pathologist, and as a surgical assistance during partial nephrectomy.  
These promising results need to be confirmed by larger in-vivo studies.  
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 Table 1. Distribution of Raman spectra. 
 
Normal (106) 
Low grade (56) 
High grade (64) Malignant (120) 
Clear cell (71) 
Other type (39) 
Total number of spectra (241) Tumoural (135) 
Benign (15) 
 
 
Table 2. Patient and tumours characteristics. 
 
Number of specimen 36 
Mean patient age (years) 59 (35-82) 
Mean tumour size (cm) 6 (2-12) 
Type of surgery: 
Open radical nephrectomy 
Laparoscopic radical nephrectomy 
Open partial nephrectomy 
Laparoscopic partial nephrectomy 
 
12 
13 
8 
3 
Pathology: 
Benign 
Malignant 
 
2 
34 
Histologic subtype of malignant tumours 
(n=34): 
Clear cell carcinoma 
Papillary 
Chromophobe 
 
 
27 
6 
1 
Tumour stage: 
pT1 
pT2 
pT3 
 
19 
3 
11 
Nodal invasion: 
N0 
N1 
 
33 
1 
Distant metastases: 
M0 
M1 
 
32 
2 
Tumour grade: 
1-2 
3-4 
 
16 
18 
Presence of necrosis inside tumour 13 
 
 
 
 Figure 1. A Raman spectrum acquired on a section of a clear-cell carcinoma. 
The background fluorescence has been removed so Raman peaks and valleys 
can be visualised.  
 
 
 
Figure 2. Experimental setting showing the Raman spectrophotometer, the 
Raman probe applied on a renal specimen, and the laptop computer on which 
optical graphs are displayed. 
 
 
 
 
 
 
Figure 3. Raman spectra of normal (orange) and tumoural (blue) renal tissue. 
For clarity, two samples of 10 tumoural and normal spectra are represented in 
the 900–1800 region of the spectrum. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Raman spectra of high-grade (orange) and low-grade (blue) RCC.  
For clarity, 10 samples of low- and high-grade tumours are displayed.  
 
 
 
Figure 5. Raman spectra of clear-cell (orange) and papillary and chromophobe 
(blue) tumours. For clarity, only 10 samples from each histologic subtype are 
represented. 
 
 
 
 
